KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its phase 2 melanoma study, Professor John F. Thompson, MD, presented an update on clinical testing of PV-10 for metastatic melanoma Wednesday, November 19th, at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. Professor Thompson noted that so far 39 of the planned 80 subjects have received at least one course of PV-10 treatment. In addition, long-term survival data for subjects participating in the phase 1 trial were presented.
